Table 3.

Demographic features.

Age at evaluation (years), mean (SD)	64.9 (11.9)
Male (%)	71
Time since diagnosis (years), mean (SD)	1.95 (3.17)
Disease duration (years), mean (SD)	8.4 (5.1)
IVIg dosage (g/kg body weight), mean (SD)	0.97 (0.24)
IVIg interval of application (weeks), mean (SD)	6.9 (5)
Duration of IVIg therapy (months)	26.2 (24.0)
CSF protein (mg/l), mean (SD)	797.0 (340.7)
CB
Median nerve baseline (%)	Yes (CB 30–50%) 17 Yes (CB > 50%) 5 No 78
Median nerve 12 months (%)	Yes (CB 30–50%) 22 Yes (CB > 50%) 0 No 78
Median nerve 24 months (%)	Yes (CB 30–50%) 43 Yes (CB > 50%) 0 No 57
Tibial nerve baseline (%)	Yes (CB 30–50%) 13 Yes (CB > 50%) 60 No 27
Tibial nerve 12 months (%)	Yes (CB 30–50%) 17 Yes (CB > 50%) 33 No 50
Tibial nerve 24 months (%)	Yes (CB 30–50%) 33 Yes (CB > 50%) 33 No 67
Nerve biopsy (%) (n)	None 38.1 (8) Positive 42.9 (9) Not clear 19.0 (4)
Time from baseline to first follow up, T1 (months), mean (SD)	10.9 (3.1)
Time from T1 to second follow up, T2 (months), mean (SD)	13.7 (1.8)

CB, conduction block; CSF, cerebral spinal fluid; IVIg, intravenous immunoglobulin; SD, standard deviation.